The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  World Health Organization Report 2007 – Global tuberculosis control surveillance, planning, financing. World Health Organization. Geneva, Switzerland (2007).
  Google Scholar
• 2  Report of the meeting of the WHO Global Task Force on XDR-TB. World Health Organization. Geneva, Switzerland, 9–10 October (2006).
  Google Scholar
• 3  Centers for Disease Control and Prevention (CDC): Extensively drug-resistant tuberculosis-United States, 1993–2006. MMWR Morb. Mortal. Wkly Rep.56(11),250–253 (2007).
  MedlineGoogle Scholar
• 4  Shah NS, Wright A, Bai GH et al.: Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis.13(3),380–387 (2007).
  Medline CASGoogle Scholar
• 5  Goldman RC, Plumley KV, Laughon BE: The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect. Disord. Drug Targets7(2),73–91 (2007).
  Medline CASGoogle Scholar
• 6  Spigelman MK: New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis.196(Suppl. 1),S28–S34 (2007).
  MedlineGoogle Scholar
• 7  Amaral L, Viveiros M, Kristiansen JE: ‘Non-antibiotics’: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr. Drug Targets7(7),887–891 (2006).
  Medline CASGoogle Scholar
• 8  Amaral L, Martins M, Viveiros M: Phenothiazines as anti-multi-drug resistant tubercular agents. Infect. Disord. Drug Targets7(3),257–265 (2007).•• Provides cogent in vitro, ex vivo and in vivo evidence that supports the use of a variety of commonly available phenothiazines for the therapy of multidrug-resistant (MDR)-TB and extensively drug-resistant (XDR)-TB.
  Medline CASGoogle Scholar
• 9  Amaral L, Martins M, Viveiros M: Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother.59(6),1237–1246 (2007).•• Covers the specific characteristics of MDR-TB and identifies a variety of agents that have potential for managing MDR-TB.
  Medline CASGoogle Scholar
• 10  Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med.328(8),521–526 (1993).
  Medline CASGoogle Scholar
• 11  Parsons LM, Somoskövi A, Urbanczik R, Salfinger M: Laboratory diagnostic aspects of drug resistant tuberculosis. Front. Biosci.9,2086–2105 (2004).
  Medline CASGoogle Scholar
• 12  Hale YM, Pfyffer GE, Salfinger M: Laboratory diagnosis of mycobacterial infections: new tools and lessons learned. Clin. Infect. Dis.33(6),834–846 (2001).
  Medline CASGoogle Scholar
• 13  Antunes ML, Aleixo-Dias J, Antunes AF, Pereira MF, Raymundo E, Rodrigues MF: Anti-tuberculosis drug resistance in Portugal. Int. J. Tuberc. Lung. Dis.4(3),223–231 (2000).
  Medline CASGoogle Scholar
• 14  Viveiros M, Leandro C, Rodrigues L et al.: Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J. Clin. Microbiol.43(9),4880–4884 (2005).•• The INNO-LiPA Rif.TB assay for the identification of Mycobacterium tuberculosis complex strains and the detection of rifampin resistance was evaluated in specimens from an area of high incidence of MDR-TB.
  Medline CASGoogle Scholar
• 15  Sam IC, Drobniewski F, More P, Kemp M, Brown T: Mycobacterium tuberculosis and rifampin resistance, United Kingdom. Emerg. Infect. Dis.12(5),752–759 (2006).
  Medline CASGoogle Scholar
• 16  Direcção Geral de Saúde: Programa Nacional De Luta Contra A Tuberculose (PNT). Ponto da Situação Epidemiológica e de Desempenho Ano 2006, 1–12. DGS, Lisboa, Portugal (2007).
  Google Scholar
• 17  Amaral L, Viveiros M, Molnar J: Antimicrobial activity of phenothiazines. In vivo18(6),725–732 (2004).
  Medline CASGoogle Scholar
• 18  Saunders BM, Britton WJ: Life and death in the granuloma: immunopathology of tuberculosis. Immunol. Cell Biol.85(2),103–111 (2007).
  MedlineGoogle Scholar
• 19  Ordway D, Viveiros M, Leandro C et al.: Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J. Infect. Chemother.8(3),227–231 (2002).
  Medline CASGoogle Scholar
• 20  Ordway D, Viveiros M, Leandro C et al.: Clinical concentrations of thioridazine kill intracellular multi-drug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother.47(3),917–922 (2003).• This study evaluated whether thioridazine (TZ) kills M. tuberculosis that has been phagocytosed by human macrophages.
  Medline CASGoogle Scholar
• 21  Ordway D, Viveiros M, Leandro C, Arroz MJ, Amaral L: Intracellular activity of clinical concentrations of phenothiazines including thioridazine against phagocytosed Staphylococcus aureus. Int. J. Antimicrob. Agents.20(1),34–43 (2002).• This study was focused on the enhancement of the killing activity of macrophages infected with Staphylococcus aureus. The concentrations of the phenothiazines used in this macrophage assay were clinically acceptable.
  Medline CASGoogle Scholar
• 22  Daniel WA, Wojcikowski J: The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol. Appl. Pharmacol.158(2),115–124 (1999).
  Medline CASGoogle Scholar
• 23  Martins M, Bleiss W, Marko A et al.: Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In vivo18(6),787–794 (2004).•• Study includes the in vitro and ex vivo effect of TZ on methicillin-resistant S. aureus. Microscopy studies were also conducted in order to evaluate the ultrastructural changes that TZ induces in bacterial cells.
  Medline CASGoogle Scholar
• 24  Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L: The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In vivo21,771–776 (2007).•• This study evaluates the effectiveness of TZ of different doses on Balb/C mice that had been infected with a massive dose of M. tuberculosis.
  Medline CASGoogle Scholar
• 25  Martins M, Ordway D, Kristiansen M et al.: Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus. Fitoterapia76(1),96–99 (2005).
  MedlineGoogle Scholar
• 26  Ordway D, Hohmann J, Viveiros M et al.: Carpobrotus edulis methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation. Phytother. Res.17(5),512–519 (2003).
  MedlineGoogle Scholar
• 27  Martins M, Schelz Z, Martins A et al.: In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis.Int. J. Antimicrob. Agents.29(3),338–340 (2007).• New derivatives of TZ were synthesized and their in vitro and ex vivo activity against M. tuberculosis was evaluated.
  Medline CASGoogle Scholar
• 28  Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. Geneva, Switzerland (2006).
  Google Scholar
• 29  Pai M, Kalantri S, Dheda K: New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert. Rev. Mol. Diagn.6(3),423–432 (2006).
  Medline CASGoogle Scholar
• 30  Palomino JC: Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr. Opin. Pulm. Med.12(3),172–178 (2006).
  Medline CASGoogle Scholar
• 31  Migliori GB, Loddenkemper R, Blasi F, Raviglione MC: 125 years after Robert Koch’s discovery of the tubercle bacillus: the new XDR-TB threat. Is ‘science’ enough to tackle the epidemic? Eur. Respir. J.29(3),423–427 (2007).
  Medline CASGoogle Scholar
• 32  Hamilton CD, Sterling TR, Blumberg HM et al.: Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin. Infect. Dis.45,338–342 (2007).
  MedlineGoogle Scholar
• 33  Martins M, Viveiros M, Amaral L: Enhanced killing of intracellular pathogenic bacteria by phenothiazines and the role of K⁺ efflux pumps of the bacterium and the killing macrophage. Anti- Infective Agents In Medicinal Chemistry7,63–72 (2008).
  CASGoogle Scholar
• 34  Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM: Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob. Agents Chemother.51(5),1627–1632 (2007).
  Medline CASGoogle Scholar
• 35  Baudoux P, Bles N, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J. Antimicrob. Chemother.59(2),246–253 (2007).
  Medline CASGoogle Scholar
• 36  Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother.58(6),1177–1184 (2006).
  Medline CASGoogle Scholar
• 37  Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion M: Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert. Rev. Anti Infect. Ther.5(5),857–871 (2007).
  Medline CASGoogle Scholar
• 38  Yew WW, Leung CC: Management of multidrug-resistant tuberculosis: Update 2007. Respirology.13(1),21–46 (2008).
  MedlineGoogle Scholar
• 39  Sungkanuparph S, Eampokalap B, Chottanapund S, Thongyen S, Manosuthi W: Impact of drug-resistant tuberculosis on the survival of HIV-infected patients. Int. J. Tuberc. Lung Dis.11(3),325–330 (2007).
  Medline CASGoogle Scholar
• 40  Ormerod LP: Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. British Med. Bull.73–74,17–24 (2005).
  Medline CASGoogle Scholar